IDEAYA Biosciences, Inc. $IDYA Shares Purchased by Cinctive Capital Management LP

Cinctive Capital Management LP increased its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 193.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 49,946 shares of the company’s stock after purchasing an additional 32,953 shares during the period. Cinctive Capital Management LP owned approximately 0.06% of IDEAYA Biosciences worth $1,359,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Aster Capital Management DIFC Ltd acquired a new stake in IDEAYA Biosciences during the 3rd quarter worth about $38,000. Abich Financial Wealth Management LLC acquired a new position in shares of IDEAYA Biosciences in the 3rd quarter valued at about $58,000. Elevation Point Wealth Partners LLC purchased a new stake in shares of IDEAYA Biosciences in the second quarter worth about $61,000. Daiwa Securities Group Inc. boosted its stake in shares of IDEAYA Biosciences by 16.1% in the second quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock worth $66,000 after buying an additional 436 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in IDEAYA Biosciences by 39.1% during the second quarter. PNC Financial Services Group Inc. now owns 3,344 shares of the company’s stock worth $70,000 after acquiring an additional 940 shares during the period. 98.29% of the stock is currently owned by institutional investors and hedge funds.

IDEAYA Biosciences Trading Up 5.1%

NASDAQ IDYA opened at $34.79 on Tuesday. The stock has a market capitalization of $3.05 billion, a price-to-earnings ratio of -26.56 and a beta of 0.09. IDEAYA Biosciences, Inc. has a twelve month low of $13.45 and a twelve month high of $39.28. The stock has a 50-day moving average of $33.80 and a 200 day moving average of $31.63.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings data on Tuesday, February 17th. The company reported ($0.94) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.09. The business had revenue of $21.75 million during the quarter, compared to analyst estimates of $5.95 million. The firm’s revenue for the quarter was up 55.7% on a year-over-year basis. During the same period in the previous year, the business posted ($1.49) earnings per share. Equities analysts predict that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

IDYA has been the subject of several recent research reports. Truist Financial lifted their price target on IDEAYA Biosciences from $59.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Wall Street Zen lowered IDEAYA Biosciences from a “buy” rating to a “sell” rating in a research report on Saturday, February 21st. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $49.00 target price on shares of IDEAYA Biosciences in a report on Wednesday, February 18th. Guggenheim reiterated a “buy” rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a research note on Wednesday, February 18th. Finally, Wedbush increased their price target on shares of IDEAYA Biosciences from $49.00 to $52.00 and gave the stock an “outperform” rating in a report on Wednesday, February 18th. Fifteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, IDEAYA Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $48.69.

Insider Activity

In other IDEAYA Biosciences news, Director Jeffrey Stein bought 50,000 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were purchased at an average price of $32.96 per share, for a total transaction of $1,648,000.00. Following the transaction, the director directly owned 54,281 shares of the company’s stock, valued at approximately $1,789,101.76. This represents a 1,167.95% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 2.50% of the stock is owned by company insiders.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.